과제정보
연구 과제 주관 기관 : The Korean Centers for Disease Control and Prevention, Ministry of Health & Welfare
참고문헌
- Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. https://doi.org/10.1016/S0140-6736(05)67394-1
- Schwartz GG, Olsson AG, Ezekowitz MD, et al. Atorvastatin for acute coronary syndromes. JAMA 2001;286:533-5.
- Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. https://doi.org/10.1056/NEJMoa040583
- Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9. https://doi.org/10.1056/NEJM199610033351401
- Lee KH, Jeong MH, Kim HM, et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. J Am Coll Cardiol 2011;58:1664-71. https://doi.org/10.1016/j.jacc.2011.05.057
- Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207. https://doi.org/10.1056/NEJMoa0807646
- Huxley RR, Barzi F, Lam TH, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation 2011;124:2056-64. https://doi.org/10.1161/CIRCULATIONAHA.111.028373
- Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020-35. https://doi.org/10.1161/CIR.0b013e31826e1058
- O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2013;82:E1-27. https://doi.org/10.1002/ccd.24776
- Giraldez RR, Giugliano RP, Mohanavelu S, et al. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVEIT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol 2008;52:914-20. https://doi.org/10.1016/j.jacc.2008.05.046
- Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000. https://doi.org/10.1001/jama.2009.1619
- Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF heart protection study of cholesterol lowering with simvastatinin 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. https://doi.org/10.1016/S0140-6736(02)09327-3
- Colquhoun D, Keech A, Hunt D, et al. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J 2004;25:771-7. https://doi.org/10.1016/j.ehj.2004.03.013
- Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-51. https://doi.org/10.1161/hc5001.100624
- Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61. https://doi.org/10.1016/S0140-6736(05)67667-2
- ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74. https://doi.org/10.1056/NEJMoa1001282
- Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. https://doi.org/10.1056/NEJMoa011090
- Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98. https://doi.org/10.1056/NEJM199011083231901
- Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95-104. https://doi.org/10.7326/0003-4819-142-2-200501180-00008
-
Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-
$\beta$ -HDL formation and increases reverse cholesterol transport. J Lipid Res 2010;51:3443-54. https://doi.org/10.1194/jlr.M008706 - Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109.
- Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008;29:2083-91. https://doi.org/10.1093/eurheartj/ehn346
피인용 문헌
- Recent Update of Korea Acute Myocardial Infarction Registry (KAMIR) vol.23, pp.4, 2016, https://doi.org/10.7793/jcoron.23.001
- Implementation of National Health Policy for the Prevention and Control of Cardiovascular Disease in South Korea: Regional-Local Cardio-Cerebrovascular Center and Nationwide Registry vol.51, pp.5, 2016, https://doi.org/10.4070/kcj.2021.0001